D37.09, Neoplasm of uncertain behavior of other specified sites of the oral cavityICD-10-CM
No Prior Auth Required
Code is covered without prior authorization (high confidence)
CGS-J15-L40386, Erythropoiesis Stimulating Agents (ESA)
J15
CGS-J15-L34356, Erythropoiesis Stimulating Agents (ESA)
J15
CGS-J15-L34200, Removal of Benign Skin Lesions
J15
CGS-J18-L34200, Removal of Benign Skin Lesions
J18
CGS-J18-L34356, Erythropoiesis Stimulating Agents (ESA)
J18
CGS-J18-L40386, Erythropoiesis Stimulating Agents (ESA)
J18
WPS-J5-L35498, Removal of Benign Skin Lesions
J5
A57482, Billing and Coding: Removal of Benign Skin Lesions
J5
A52450, Billing and Coding: Paclitaxel (e.g., Taxol/Abraxane )
J6
NGS-J6-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses
J6
NGS-J6-L36850, Peripheral Nerve Blocks
J6
NGS-J6-L40333, Erythropoiesis Stimulating Agents
J6
NGS-J6-L40334, Erythropoiesis Stimulating Agents
J6
A57452, Billing and Coding: Peripheral Nerve Blocks
J6
WPS-J8-L35498, Removal of Benign Skin Lesions
J8
FIRST_COAST-L33933, Peripheral Nerve Blocks
J9
NGS-JK-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses
JK
NGS-JK-L40333, Erythropoiesis Stimulating Agents
JK
NGS-JK-L36850, Peripheral Nerve Blocks
JK
NGS-JK-L40334, Erythropoiesis Stimulating Agents
JK
Ask Backwork about documentation requirements, denial risks, or coverage in your state.